Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules

European Journal of Gastroenterology and Hepatology

Volumn 14, Issue 12, 2002, Pages 1357-1362

  Edsbäcker, Staffan ^a   Larsson, Per ^b   Wollmer, Per ^c  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Absorption; Budesonide; Crohn's disease; Formulation; Pharmacokinetics

Indexed keywords

BUDESONIDE; CORTICOSTEROID; DEUTERIUM; INDIUM 111;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL TRIAL; COLON ABSORPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG EXCRETION; DRUG LABELING; FOOD INTAKE; GASTROINTESTINAL TRACT SCINTISCANNING; HUMAN; HUMAN EXPERIMENT; INTESTINE TRANSIT TIME; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINE ABSORPTION; STOMACH EMPTYING;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; BUDESONIDE; CAPSULES; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED;

EID: 0036928030     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200212000-00012     Document Type: Article

References (14)

1. Brogden R, McTavish D. Budesonide. An updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs 1992; 44:375-407.
2. Hanauer SB, Stathopoulos G. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf 1991; 6:192-219.
3. Edsbäcker S. Budesonide capsules: Scientific basis. Drugs of Today 2000; 36:9-23.
4. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994; 331:836-841.
5. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997; 41:209-214.
6. Thomsen O.Ø, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998; 339:370-374.
7. Lundin P, Naber T, Nilsson M, Edsbäcker S. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease. Aliment Pharmacol Ther 2001; 15:45-51.
8. Lindberg C, Blomqvist A, Paulson J. Determination of (22R,S)budesonide in human plasma by automated liquid chromatography/thermospray mass spectrometry. Biol Mass Spectrom 1992; 21:525-533.
9. Proost JH. Application of a numerical deconvolution technique in the assessment of bioavailability. J Pharm Sci 1985; 74:1135-1136.
10. Brattsand R. Overview of newer glucocorticosteroid preparations for IBD. Can J Gastroenterol 1990; 4:407-414.
11. Ryrfeldt A, Andersson P, Edsbäcker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl 1982; 122:86-95.
12. Miller LR, Vitti R, Maurer A, Siegel J, Golazeski T, Kresky B, Small intestinal transit in symptomatic Crohn's disease. Gastroenterology 1989; 96:A344.
13. Mundy MJ, Wilson CG, Hardy JG. The effect of eating on transit through the small intestine. Nucl Med Commun 1989; 10:45-50.
14. Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res 1991; 8:360-364.